Sanovel Returns from International Pharmaceutical Chemistry Congress with Award

Sanovel, a leading company in the Turkish pharmaceutical sector, has been recognized with a second-place award in the "2023 Pharmaceutical R&D Brand Count" category at the 13th International Pharmaceutical Chemistry Congress organized by the Chemical Engineers Association.

Sanovel, which continues its activities on the path to becoming a global pharmaceutical company with its strong R&D, high-standard products and specialized human resources, received the second-place award in the "2023 Pharmaceutical R&D Brand Count" category at the Crystal Mortar Awards presented at the 13th International Pharmaceutical Chemistry Congress.

Sanovel, which was recognized with first-place awards in the "2022 Pharmaceutical R&D National Patent Count" and "2022 Pharmaceutical R&D Brand Count" categories at the Crystal Mortar Awards held last year, received great recognition again this year with its R&D investments.

Sanovel leads the sector with R&D success
Sanovel, which directs the Turkish pharmaceutical industry with its strong R&D, high-standard products, scientific and technological infrastructure and achievements in patents, continues to lead the Turkish pharmaceutical sector in the number of patent applications and registrations.

Sanovel, which was also included in the "List of Top 25 Companies Filing the Most Patents" prepared using 2023 data from the European Patent Office, achieved the distinction of being the "only Turkish company" on the list by ranking 18th in the Pharmaceuticals field.

According to data from the "R&D 250 Research" prepared by economics and business magazine Turkishtime, Sanovel, which is listed among the top 10 companies allocating the most resources to R&D in the pharmaceutical sector, also ranked 2nd in the "Top 50 Companies by Number of Brands Obtained at R&D Centers" ranking in the same research, thereby validating its success in R&D.